In January 2015, SCIRENT has begun with the recruitment for ETiCS trial in Clinical center of Serbia in Belgrade. Five patients have been screened up to date and one was successfully enrolled in the study.
ETiCS is a new diagnostic, prospective, multicenter trial which will be carried out in Croatia, Germany and Serbia. It is meant to explore the production of autoantibodies directed against beta1-adrenoceptors in patients with acute myocarditis. This trial aims at answering the question regarding the role of immune system and production of anti-beta1-autoantibodies in the onset of heart failure. Another goal is to explore if these autoantibodies affect the course of heart failure and in which way.